A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”

Sophie M. Ernst; Jan H. von der Thüsen; Hendrikus J. Dubbink; Anne Marie C. Dingemans

doi:10.1016/j.jtho.2024.07.001

A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”

Sophie M. Ernst, Jan H. von der Thüsen, Hendrikus J. Dubbink, Anne Marie C. Dingemans^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	e44-e45
Journal	Journal of Thoracic Oncology
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/j.jtho.2024.07.001
Publication status	Published - Sept 2024

Access to Document

10.1016/j.jtho.2024.07.001

1-s2.0-S1556086424006658-mainFinal published version, 90.8 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{e555dbcfa9f542058a778b9360cbaab8,

title = "A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”",

author = "Ernst, {Sophie M.} and {von der Th{\"u}sen}, {Jan H.} and Dubbink, {Hendrikus J.} and Dingemans, {Anne Marie C.}",

year = "2024",

month = sep,

doi = "10.1016/j.jtho.2024.07.001",

language = "English",

volume = "19",

pages = "e44--e45",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "9",

}

A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”. / Ernst, Sophie M.; von der Thüsen, Jan H.; Dubbink, Hendrikus J. et al.
In: Journal of Thoracic Oncology, Vol. 19, No. 9, 09.2024, p. e44-e45.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - A Response to the Letter to the Editor

T2 - Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”

AU - Ernst, Sophie M.

AU - von der Thüsen, Jan H.

AU - Dubbink, Hendrikus J.

AU - Dingemans, Anne Marie C.

PY - 2024/9

Y1 - 2024/9

UR - http://www.scopus.com/inward/record.url?scp=85201308639&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2024.07.001

DO - 10.1016/j.jtho.2024.07.001

M3 - Comment/Letter to the editor

C2 - 39242150

AN - SCOPUS:85201308639

SN - 1556-0864

VL - 19

SP - e44-e45

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 9

ER -

A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”

Access to Document

Other files and links

Cite this